BioCentury | Aug 8, 2018
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture and mouse studies suggest activating PP2A could help treat KRAS-mutant lung cancer. In two human KRAS-mutant lung cancer lines, a previously reported tricyclic sulfonamide-based PP2A activator plus the MEK inhibitor...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Other

INDICATION: Other / Genetic disorders Mouse studies suggest that inhibiting PP2A could treat MECP2 duplication syndrome, an X-linked genetic disorder with neuromotor, developmental and other symptoms. In a mouse model of the syndrome, tool compounds...
BioCentury | Jul 18, 2017
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture and mouse studies suggest activating PP2A could help treat K-Ras (KRAS)-mutant lung cancer. In five KRAS-mutant human lung cancer cell lines, a previously reported PP2A activator decreased survival compared with...
BioCentury | Jun 23, 2014
Emerging Company Profile

Dual: Multi-pronged attack

Dual Therapeutics LLC is developing first-in-class oral small molecules that directly activate protein phosphatase 2 to disrupt multiple cancer pathways simultaneously. By restoring the phosphatase's activity to normal levels, the approach could treat prostate cancers...
Items per page:
1 - 4 of 4